$ATOS Updated corporate presentation as of today. Not much has changed in regards to their pipeline and expected upcoming milestones. I believe the 3rd (out of 4) cohort from AT-301 nasal spray should be completed and PR’d within the next week or two. Still waiting on regulatory approval for AT-H201 inhalation therapy so that’s still a wild card for me. atossatherapeutics.com/wp-c...
  • 7
Here’s a graphic of their development strategy. Nasal spray obviously far ahead of their inhalation therapy (still seeking approval) so somewhat frequent/significant updates on that will be key. Approval for AT-H201 will definitely add pipeline value but the longer it takes to get approved, the less I see it making an impact on SP.
  • 1
1 Like